Summary
All extracted patent/legal-protection claims are not supported by the provided FDA-approved Xarelto prescribing information because no relevant label sections regarding patents, exclusivity, or legal protection were provided. No on-label safety, dosing, contraindications, warnings, interactions, or population information was evaluated.
Category Scores
Accurate Statements
Unsupported Statements
Xarelto has multiple patents and multiple types of legal protection (e.g., composition of matter patents, formulation/process patents, and possible periods of exclusivity).
No relevant FDA label sections were provided regarding patents, exclusivity, or legal protection types.
Patent expiry for Xarelto is not a single date; the relevant expiry depends on which specific patent a generic or biosimilar applicant is targeting.
No relevant FDA label sections were provided regarding patent expiry timing or how it varies by targeted patent.
Different patents may expire on different dates for Xarelto.
No relevant FDA label sections were provided regarding specific patents or their expiration.
Generic entry may be determined by the expiry/overlap of the specific patents a generic applicant challenges.
No relevant FDA label sections were provided regarding generic entry timing or patent-challenge framework.
A generic may be able to launch based on the expiry/overlap of the specific patents it challenges, not necessarily the earliest one shown.
No relevant FDA label sections were provided regarding generic launch timing relative to patent overlap.
A generic or alternate manufacturer may enter even when some patents remain active if it does not infringe the remaining active patents.
No relevant FDA label sections were provided regarding infringement considerations for alternate manufacturers.
A generic or alternate manufacturer may enter if remaining patents are no longer enforceable, for example if a patent is invalidated or settled.
No relevant FDA label sections were provided regarding patent invalidation, settlement, or enforceability.
Xarelto patent protection is typically not dose-specific.
No relevant FDA label sections were provided regarding whether patent protection is dose-specific.
Contradictions
Important Omissions
No evaluation was performed against FDA prescribing information for contraindications, boxed warnings, dosage/administration, warnings/precautions, drug interactions, adverse reactions, monitoring, storage, or use in specific populations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated content concerns patent/legal-protection concepts and does not provide or omit clinical dosing/safety instructions in the supplied material; however, it is entirely unsupported by the provided prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All claims are unsupported by the provided FDA label content because no relevant prescribing-information sections regarding patents/exclusivity were supplied.
Suggested Improvement
Limit evaluation and statements to content present in the FDA-approved Xarelto prescribing information provided in the prompt (e.g., indications, dosage/administration, contraindications, warnings/precautions, interactions, adverse reactions, and labeled populations).